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Introduction
Genetic background of essential thrombocythemia (ET) is not well known as yet. The most frequently, sporadic cases of ET are observed, but patients with ET family history are also noted, what suggests a hereditary nature of the disease (1) (2) . Various reports on the association between acquired and inherited gene mutations and risk of ET were presented, but the impact of constitutional mutations of tumor susceptibility genes, e.g. CHEK2, on the disease development has not been studied to date.
CHEK2 is the tumor suppressor gene, that protects cells against too rapid, uncontrolled growth by regulating of cell division. It encodes cell cycle G2 checkpoint kinase, which is a key mediator in cellular response to various DNA damages. The CHEK2 kinase is activated on ATM-dependent pathways and then phosphorylates substrates, such as p53, BRCA1, CDC25A and CDC25C, involved in the cell cycle checkpoint control through coordination of DNA repair, cell cycle progression and apoptosis (3).
Germline CHEK2 mutations (i.e. 1100delC, I157T) were found in Li-Fraumeni syndrome (4), some lymphoid malignancies (5-7), and also in myeloid malignancies, e.g. myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with a low frequency (6, 8 ). Collado et al. (9) described lack of CHEK2 germline mutations in Spanish patients with AML. However, the author noted that association of these mutations with cancer risk depends mainly on their incidence in general population. Lack of a mutation or its very low frequency in the control and study groups, make the presence of this mutation clinically irrelevant (9) .
Constitutional mutations of CHEK2 were reported in many types of solid tumors, including breast, ovary, colon, prostate and thyroid gland cancers. It was estimated that CHEK2 mutations cause low to moderate genetic risk of solid tumors development (10) (11) (12) (13) (14) .
In the general Polish population the most common are the I157T missense mutation (4.8% frequency) and three premature protein-truncating mutations: IVS2+1G>A, del5395 and 1100delC (0.4%, 0.4% and 0.2% frequency, respectively) (15) . The splice-site mutation IVS2+1G>A results from nucleotide transition G→A and 4-bp insertion in the mutant transcript, due to an abnormal splicing between exons 2 and 3. The 5,395-bp deletion includes exon 9 and 10 (16).
In this report we present the results of our research on association between above mentioned four CHEK2 mutations and a risk of ET. The relationship between a congenital CHEK2 mutation and the acquired V617F mutation of the Janus tyrosine kinase 2 gene (JAK2), the important marker of myeloproliferative neoplasms (17) , was also investigated, as well as its relation to patients' age, hematologic features at ET diagnosis, as well as family history of cancer.
Design and Methods
Patients
A total of 106 consecutive patients, newly diagnosed with ET according to WHO 2008 criteria (18) in two Polish hematological centers (Wrocław and Toruń), were involved in the study. The median age at ET diagnosis was 56.5 years (≈57 years; range 20-85). For each patient, data from medical records were collected: hemoglobin and hematocrit level, white blood cells (WBC) count and platelets (PLT) count at ET diagnosis.
In families with suspicion of a congenital CHEK2 mutation, molecular tests were performed (8 out of 16 invited families agreed to testing -a total of 22 persons).
59% of ET patients originated from families with at least one case of cancer diagnosed in a close relative. The most frequent were breast, lung, colon, stomach, pancreas, prostate and ovary cancer, as well as acute or chronic leukemia (in 6 families), or ET (in 4 families).
One family fulfilled Li-Fraumeni-like syndrome criteria (19) . In families of four patients (diagnosed with ET at age of 34, 62, 61 and 62) another ET case was diagnosed in daughter at age of 14, mother at age of 53, sister at age of 56, and brother at age of 60, respectively. 43 out of 106 (41%) ET patients originated from families with no other cancer case. 
Molecular analysis
The CHEK2 mutations were investigated in DNA from peripheral blood leukocytes, extracted by standard salting-out method. The constitutional character of mutations was verified in mutation-positive patients by analysis of DNA from buccal swabs, extracted using Swab-Extract DNA Purification Kit (EURx, Poland). The I157T and IVS2+1G>A were examined by RFLP-PCR (20) , the 1100delC by ASO-PCR (20) , and the del5395 by multiplex-PCR with two primer pairs flanking breakpoint sites in introns 8 and 10 (15).
Mutation-positive cases were confirmed by sequencing analysis using ABI-PRISM 3130
Genetic Analyzer (Applied Biosystems, USA). The JAK2 V617F mutation was detected in DNA from peripheral blood and from buccal swabs by allele-specific PCR described by Jones et al. (21), and cases with suspicion of homozygosity were examined by sequencing analysis.
Statistical analysis
Statistical analysis included a comparison of the prevalence of variant alleles in the studied and control groups, calculation of odds ratios (ORs) from two-by-two tables, and calculation of statistical significance of differences between tested groups using the Fisher's exact test. Moreover, values of median and arithmetic mean (and standard deviation) of the age and hematological parameters at ET diagnosis in groups of patients were calculated and compared. All calculations were performed using program for Windows: Interactive Statistical Calculation Pages.
Results and Discussion
Analysis of CHEK2 mutations
A CHEK2 mutation was found in 16 out of 106 ET patients (15.1%). All mutations detected in DNA from peripheral blood were also found in DNA from buccal swabs, what confirmed their constitutional character. They were significantly more frequent in the group of ET patients than in both control groups and were associated with the increased ET risk (our controls: 4.5%; OR=3.8; p=0.002; the general Polish population: 5.8%; OR=2.9; p=0.0005).
The elevated risk of ET also was showed in subgroups of patients: with IVS2+1G>A only, with protein-truncating mutations together, and with I157T only (Table 1 ). The ET risk for carriers of congenital CHEK2 mutations, turned out to be comparable with their risk of breast or prostate cancer (12, 15) .
Among patients with ET diagnosed under the age of 57 (the median age at ET diagnosis) the prevalence of CHEK2 mutations (except IVS2+1G>A) was significantly higher than among patients diagnosed with ET at/above this age, in relation to both controls.
The IVS2+1G>A frequency was statistically higher in the group of ET patients with ET diagnosed in the older age -only in relation to the general Polish population (Table 1) .
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The I157T mutation occurs in exon 3 within the highly conserved protein-interaction domain FHA (forkhead homology-associated), basic for the CHEK2 activation after DNA The median age at ET diagnosis in 16 CHEK2 mutation carriers was 4 years lower than the median calculated for non-carriers, but this difference was not statistically significant (53 vs. 57 years; p=0.14). We also showed no correlation of CHEK2 mutations with any hematological parameters, basic for proper diagnosis of ET ( Table 2 ).
The investigation of 8 families confirmed a hereditary character of mutations disclosed in ET patients by their detection in first and second degree relatives. (Figure 1 A-H) . Out of 16 patients with a CHEK2 mutation, 7 (44%) originated from families with organ cancers (4 of the families are presented in Figure 1 A-D) . In the family with LFL syndrome, I157T was disclosed in the ET patient, in his healthy mother and her sister's healthy son (sister died from breast cancer diagnosed at age of 37), whereas in patient's healthy father, and in brother with childhood ALL the I157T was not found (Figure 1 C) . However, among the four families with two cases of ET in only one a hereditary CHEK2 mutation was shown. In this family I157T was detected in 3 persons from three successive generations, among whom two were diagnosed with ET (Figure 1 D) . 9 (21%) of CHEK2-positive ET patients originated from families with no other cancer case (4 of the families are presented in Figure 1 E-H). These results suggest that CHEK2 mutations are rather associated with sporadic ET than with the familial one, although to confirm this observation a larger group of sporadic and familial ET cases should be tested.
Analysis of the JAK2 V617F
The V617F mutation was found in 61 (58%) patients, one of whom was homozygous.
However, in the group of patients with ET diagnosed under the age of 57 the frequency of V617F was much lower (49%) than in the group with ET diagnosed at/above this age (66%) ( Table 2 ). The V617F was not disclosed in DNA from buccal swabs of ET patients, in DNA from peripheral blood of our controls, and in all but one of patients relatives (from 8 families).
V617F was found in the daughter (diagnosed with ET at age of 14) of the woman (diagnosed with ET at age of 34) (Figure 1 D) . The homozygosity of V617F was detected in patient with CHEK2 I157T (age at ET onset 50 years), whose family did not consent to molecular studies (Table 2 ).
In the group of ET patients with V617F, compared to the group without it, the medians of hemoglobin and hematocrit level, as well as the WBC count at disease diagnosis were significantly higher, whereas the median of the PLT count was significantly lower, what confirmed observations of many authors. Moreover, the median age at ET diagnosis among V617F positive patients was 5 years higher than among V617F negative patients, but this difference turned out not to be statistically important (54 vs. 59 years; p=0.19) ( Table 2) .
Correlation of CHEK2 mutations (CHEK2+) with the JAK2 V617F (JAK2+)
The acquired JAK2 V617F mutation was found in 9/16 (56%) of ET patients, carriers of congenital CHEK2 mutation. In 6/9 (67%) of CHEK2+/JAK2+ patients, ET was diagnosed under the age of 57.
The medians of hematological parameters at ET diagnosis in the groups of CHEK2+/JAK2+ and CHEK2-/JAK2+ patients were similar. However, the median age at ET diagnosis among CHEK2+/JAK2+ patients turned out to be seven years lower than among CHEK2-/JAK2+ patients (52 vs. 59 years; p=0.04) ( Table 2 ).
These results suggest that in hereditarily predisposed individuals, with dysfunction of the tumor suppressor CHEK2 gene, performing a key role in regulation of the cell cycle, easier and faster acquisition of JAK2 V617F mutation may occur, leading to clinical consequences at younger age. However, it should be noted that the V617F was detected in only 9/16 of ET patients with a CHEK2 mutation, therefore, further studies should be done to verify, whether in CHEK2+/JAK2V617F-patients other mutations of JAK2 are present. They should also include an analysis of JAK2 46/1 haplotype, which increases the risk of ET regardless of the acquisition of V617F (23), and its relation with CHEK2 mutations.
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On the basis of the obtained results we can conclude, that CHEK2 gene mutations could potentially contribute to the susceptibility to ET. The germline inactivation of CHEK2, as it seems, has no direct impact on the development of ET, but it can cause disruption of cell cycle checkpoints and initiate or support the ET cancerogenic process at younger age.
Authorship and Disclosures
HJ designed the study, performed statistical analysis and interpretation of results, and wrote the paper; AB, MP, MS, AJC and BJ designed and performed the laboratory research; MKJ, MC and DW recruited the patients and analyzed their clinical and hematological data; KK and OH assisted in study design, analysis and interpretation of results, and revised the manuscript critically for important intellectual content; The authors reported no potential conflicts of interest. Legend to the Figure   Figure 1 . (A-F) Families with the CHEK2 I157T mutation. (G) The family with the CHEK2 IVS2+1G>A mutation. (H) The family with the CHEK2 1100delC mutation. Black symbols designate persons affected by cancer. The age of cancer onset is given after the disease symbol or above the arrow indicating a proband. ET-essential thrombocythemia, ALL-acute lymphoblastic leukemia, Br-breast cancer, St-stomach cancer, Pr-prostate cancer, Ki-kidney cancer. Persons who were not tested are designated-n.t. The presence of a mutation is designated +, absence -. Figure 1 .
